Oxytocin: Its role in benign prostatic hyperplasia via the ERK pathway

Clinical Science

Volumn 131, Issue 7, 2017, Pages 595-607

  Xu, Huan ^a   Fu, Shi ^a   Chen, Yanbo ^a   Chen, Qi ^a   Gu, Meng ^a   Liu, Chong ^a   Qiao, Zhiguang ^a   Zhou, Juan ^a   Wang, Zhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; OXYTOCIN; OXYTOCIN ANTAGONIST;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HORMONE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; MALE; MORPHOLOGY; MOUSE; NONHUMAN; OXYTOCIN BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CELL; PROSTATE HYPERTROPHY; PROSTATE TISSUE; PROSTATE VOLUME; TISSUE LEVEL; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; EPITHELIUM CELL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; STROMA CELL;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; OXYTOCIN; PROSTATE; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES; STROMAL CELLS;

EID: 85016434183     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20170030     Document Type: Article

References (40)

1. Berry, S. J., Coffey, D. S., Walsh, P. C. and Ewing, L. L. (1984) The development of human benign prostatic hyperplasia with age. J. Urol. 132, 474-479.
2. Marker, P. C., Donjacour, A. A., Dahiya, R. and Cunha, G. R. (2003) Hormonal, cellular, and molecular control of prostatic development. Dev. Biol. 253, 165-174.
3. De Nunzio, C., Aronson, W., Freedland, S. J., Giovannucci, E. and Parsons, J. K. (2012) The correlation between metabolic syndrome and prostatic diseases. Eur. Urol. 61, 560-570.
4. Vikram, A., Jena, G. B. and Ramarao, P. (2010) Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia. Prostate 70, 79-89.
5. Hammarsten, J. and Hogstedt, B. (2001) Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur. Urol. 39, 151-158.
6. Lepor, H. (2004) Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev. Urol. 6 (Suppl 9), S3-S10
7. MacDonald, A. A., Herbison, G. P., Showell, M. and Farquhar, C. M. (2010) The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum. Reprod. Update 16, 293-311.
8. Peters, A., Pellerin, L., Dallman, M. F., Oltmanns, K. M., Schweiger, U., Born, J. et al. (2007) Causes of obesity: looking beyond the hypothalamus. Prog. Neurobiol. 81, 61-88.
9. Porcaro, A. B., Petrozziello, A., Ghimenton, C., Migliorini, F., Sava, T., Caruso, B. et al. (2012) Along the pituitary-testis-prostate axis, serum total testosterone is a significant preoperative variable independently contributing to separating the prostate cancer population into prostatectomy Gleason score groups. Anticancer Res 32, 5015-5022.
10. Altirriba, J., Poher, A. L., Caillon, A., Arsenijevic, D., Veyrat-Durebex, C., Lyautey, J. et al. (2014) Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes. Endocrinology 155, 4189-4201.
11. Nicholson, H. D. (1996) Oxytocin: a paracrine regulator of prostatic function. Rev. Reprod. 1, 69-72.
12. Whittington, K., Assinder, S., Gould, M. and Nicholson, H. (2004) Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate. Cell Tissue Res. 318, 375-382.
13. Whittington, K., Connors, B., King, K., Assinder, S., Hogarth, K. and Nicholson, H. (2007) The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate. Prostate 67, 1132-1142.
14. Sendemir, A., Sendemir, E., Kosmehl, H. and Jirikowski, G. F. (2008) Expression of sex hormone-binding globulin, oxytocin receptor, caveolin-1 and p21 in leiomyoma. Gynecol. Endocrinol. 24, 105-112.
15. Montorsi, F., Roehrborn, C., Garcia-Penit, J., Borre, M., Roeleveld, T. A., Alimi, J. C. et al. (2011) The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int. 107, 1426-1431.
16. Berquin, I. M., Min, Y., Wu, R., Wu, H. and Chen, Y. Q. (2005) Expression signature of the mouse prostate. J. Biol. Chem. 280, 36442-36451.
17. Harmelin, A., Danon, T., Kela, I. and Brenner, O. (2005) Biopsy of the mouse prostate. Lab. Anim. 39, 215-220.
18. Corona, G., Vignozzi, L., Rastrelli, G., Lotti, F., Cipriani, S. and Maggi, M. (2014) Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int. J. Endocrinol. 2014, 329456.
19. Park, Y. W., Kim, S. B., Kwon, H., Kang, H. C., Cho, K. et al. (2013) The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology 82, 674-679.
20. Kim, W. T., Yun, S. J., Choi, Y. D., Kim, G. Y., Moon, S. K., Choi, Y. H. et al. (2011) Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J. Korean Med. Sci. 26, 1214-1218.
21. Sendemir, E., Herbert, Z., Sivukhina, E., Zermann, D. H., Arnold, R. and Jirikowski, G. F. (2008) Colocalization of androgen binding protein, oxytocin receptor, caveolin 1 and proliferation marker p21 in benign prostate hyperplasia. Anatomia Histol. Embryol. 37, 325-331.
22. Qian, W., Zhu, T., Tang, B., Yu, S., Hu, H., Sun, W. et al. (2014) Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. J. Clin. Endocrinol. Metab. 99, 4683-4689.
23. Vikram, A., Jena, G. and Ramarao, P. (2010) Pioglitazone attenuates prostatic enlargement in diet-induced insulin-resistant rats by altering lipid distribution and hyperinsulinaemia. Br. J. Pharmacol. 161, 1708-1721.
24. Morales, C. R. and Badran, H. (2003) Prosaposin ablation inactivates the MAPK and Akt signaling pathways and interferes with the development of the prostate gland. Asian J. Androl. 5, 57-63.
25. Giovannucci, E., Rimm, E. B., Chute, C. G., Kawachi, I., Colditz, G. A., Stampfer, M. J. et al. (1994) Obesity and benign prostatic hyperplasia. Am. J. Epidemiol. 140, 989-1002.
26. Tentolouris, N., Liatis, S. and Katsilambros, N. (2006) Sympathetic system activity in obesity and metabolic syndrome. Ann. N. Y. Acad. Sci. 1083, 129-152
27. Kluth, L. A., Shariat, S. F., Kratzik, C., Tagawa, S., Sonpavde, G., Rieken, M. et al. (2014) The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J. Urol. 32, 669-676.
28. Bodanszky, M., Sharaf, H., Roy, J. B. and Said, SI. (1992) Contractile activity of vasotocin, oxytocin, and vasopressin on mammalian prostate. Eur. J. Pharmacol. 216, 311-313.
29. Frayne, J., Townsend, D. and Nicholson, H. D. (1996) Effects of oxytocin on sperm transport in the pubertal rat. J. Reprod. Fertil. 107, 299-306.
30. Plecas, B., Popovic, A., Jovovic, D. and Hristic, M. (1992) Mitotic activity and cell deletion in ventral prostate epithelium of intact and castrated oxytocin-treated rats. J. Endocrinol. Invest. 15, 249-253.
31. Assinder, S. J., Johnson, C., King, K. and Nicholson, H. D. (2004) Regulation of 5alpha-reductase isoforms by oxytocin in the rat ventral prostate. Endocrinology 145, 5767-5773.
32. Xiao, D., Chinnappan, D., Pestell, R., Albanese, C. and Weber, H. C. (2005) Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells. Cancer Res. 65, 9934-9942.
33. Carriere, A., Ray, H., Blenis, J. and Roux, P. P. (2008) The RSK factors of activating the Ras/MAPK signaling cascade. Front. Biosci. 13, 4258-4275.
34. Schouten, G. J., Vertegaal, A. C., Whiteside, S. T., Israel, A., Toebes, M., Dorsman, J. C. et al. (1997) IkappaB alpha is a target for the mitogen-activated 90. kDa ribosomal S6 kinase. EMBO J. 16, 3133-3144.
35. Ballif, B. A. and Blenis, J. (2001) Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 12, 397-408.
36. Baliga, R. R., Pimental, D. R., Zhao, Y. Y., Simmons, W. W., Marchionni, M. A., Sawyer, D. B. et al. (1999) NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. Am. J. Physiol. 277 5 Pt 2, H2026-H2037.
37. Ghoda, L., Lin, X. and Greene, W. C. (1997) The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J. Biol. Chem. 272, 21281-22228.
38. Leontieva, O. V., Demidenko, Z. N. and Blagosklonny, M. V. (2013) MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Differ. 20, 1241-1249.
39. Anjum, R. and Blenis, J. (2008) The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol. 9, 747-758.
40. Vikram, A., Jena, G. and Ramarao, P. (2010) Insulin-resistance and benign prostatic hyperplasia: the connection. European J. Pharmacol. 641, 75-81.